ChemomAb’s CM-101 Receives FDA Clearance for Phase 2 trial in Adults with Systemic Sclerosis (SSc)
ChemomAb Ltd. has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to assess CM-101 in a Phase 2 trial for systemic sclerosis (SSc ...
HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients
[vc_row][vc_column][vc_custom_heading text="HER2+/- Metastatic Breast Cancer Prevalence vs. Treated Patients" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_r ...
USA – Systemic Treatment Pathway Recurrent GBM Patients
[vc_row][vc_column][vc_custom_heading text="USA - Systemic Treatment Pathway Recurrent GBM Patients" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc_co ...
Genetic mutations associated with Alzheimer’s disease risk
[vc_row][vc_column][vc_custom_heading text="Genetic mutations associated with Alzheimer’s disease risk" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc ...
FDA Approves Neuren Pharmaceutical’s Phase II Trial of NNZ-2591 for Prader-Willi Syndrome
The FDA has approved Neuren Pharmaceuticals' Phase 2 clinical trial for its NNZ-2591 drug for children with Prader-Willi syndrome, a neurological disorder with no approved treatment options. The trial ...